Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has secured a critical professorship in vaccinology for the future following a gift of £3.33 million from the Saïd family. The gift will enable Professor Sarah Gilbert, the inaugural post holder, to continue her ground-breaking research in the field, while also helping to ensure that Oxford remains at the forefront of vaccine development for generations to come.

Professor Sarah Gilbert at the Jenner Institute © University of Oxford / John Cairns

Professor Gilbert has 25 years of experience in the development of vaccines against malaria, influenza and emerging and re-emerging viral pathogens, including Lassa, Nipah and Middle East Respiratory Syndrome (MERS). In 2018 she began preparing for “Disease X”, the World Health Organisation’s term for a hypothetical, unknown pathogen that could cause a future epidemic. This preparation proved essential when, in January 2020, reports from China alerted the world to a new viral threat.

The genetic sequence of SARS-CoV-2 was released on 11 January and later that same day, Professor Gilbert and her team began designing Oxford’s COVID-19 vaccine: ChAdOx1 nCoV-19. Underpinned by Professor Gilbert’s research into vaccines that work by inducing strong and protective T cell responses, ChAdOx1 nCoV-19 became the first COVID-19 vaccine to enter into Phase III clinical trials. Professor Gilbert is currently working with the Oxford Vaccine Group, teams within the Jenner Institute and a network of international collaborators to test its efficacy in over 20,000 trial participants around the world.

The full story is available on the University of Oxford's Development Office website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.